Lipoprotein particles LpA-I, LpA-I: A-II and LpB in patients with coronary artery disease;Partículas lipoproteicas LpA-I, LpA-I: A-II y LpB en enfermedad coronaria

Revista Medica de Chile

Volumn 128, Issue 1, 2000, Pages 9-16

  Calvo M, Carlos ^a   Olmos C, Alfonso ^a   Ulloa M, Natalia ^a   Bustos A, Alejandra ^a   Toledo B, Lorena ^a   Durán S, Daniel ^a   Naveas, Rina ^a  

^a UNIVERSITY OF CONCEPCIÓN   (Chile)

Author keywords

Cholesterol; Coronary disease; HDL cholesterol; Lipoproteins

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; BLOOD; CASE CONTROL STUDY; CORONARY ARTERY DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; NONPARAMETRIC TEST; RISK; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; APOLIPOPROTEINS A; APOLIPOPROTEINS B; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; RISK FACTORS; STATISTICS, NONPARAMETRIC;

EID: 0033642381     PISSN: 00349887     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. TAUCHER E, ALBALA C, PÉREZ P. ¿Ha aumentado la mortalidad cardiovascular en Chile? Rev Méd Chile 1990; 118: 225-34.
2. SCHWARTZ CJ, VALENTE AI, HIDERBRAND EF. The pathogenesis of atherosclerosis and coronary artery disease: an evolving consensus. In: NW Horizons in Coronary Heart Disease. Edit G Born and Schwartz. Current Science 1993; 1: 1-10.
3. TAILLEUX A, FRUCHART JC. HDL heterogeneity and atherosclerosis. Clin Rev Clin Lab Sc 1996; 33 : 1-39.
4. DAVEY G, SONG F, SHELDON T. Cholesterol lowering and mortality: The importance of considering initial level of risk. BMJ 1993; 306: 1367-77.
5. STAMLER CJ, WENTWORTH D, NEATON ID. Is relationship between serum cholesterol and risk of premature death from coronary disease a continuos or graded. Finding in 356.222 primary screenees of the multiple risk intervention trials (MRFIT). JAMA 1986; 256: 2823-32.
6. ALAUPOVIC P, WANG C, MC CONATHY WJ, WEISER D, DOWNS D. Lipolytic degradation of human very low density lipoproteins by human milk lipoprotein lipase: Identification of lipoprotein B as the main lipoprotein degradation product. Arch Biochem Biophys 1986; 244: 228-37.
7. GORDON T, CASTELLI WP, HJORTLAND MC, KANNEL WB, DAWBER TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham study. Am J Med 1977; 62: 707-14.
8. MILLER EN, FORDE OH, THELLE DS, MJOS OD. The Trombo Heart Study: High density lipoprotein and coronary heart disease: a prospective case control study. Lancet 1977; 1: 965-.
9. CHEUNG MC, ALBERS JJ. Characterization of lipoprotein particles isolated by immunoaffinity chromatography. Particles containing A-I and A-II and particles containing A-I but not A-II. J Biol Chem 1984; 259: 12201-9.
10. CALVO C, BUSTOS A, SEPÚLVEDA J, ULLOA N, SEPÚLVEDA V. Development of monoclonal antibodies for the selective isolation of human apolipoprotein A-containing particles. Hybridoma 1995; 14: 603-8.
11. CALVO C. Mab 3F5 antiapolipoprotein A-II, Mab 6B9 anti high density lipoprotein (HDL) and Mab FF9 anti apolipoprotein A-I. Hybridoma 1995; 14: 626-8.
12. CALVO C, BUSTOS A, GIRAUDO P, ULLOA N, SEPÚLVEDA J, VERDUGO C, TOLEDO L. A monoclonal antibody-based enzyme immunoassay for the measurement of native and glycated apolipoprotein B-containing particles. J Atheros Thromb 1997; 4: 57-61.
13. BUSTOS P, CALVO C, ULLOA N, QUIROGA A, SEPÚLVEDA J. An immunoenzymatic procedure for human apo B-containing particles quantification using monoclonal antibodies. Hybridoma 1998; 17: 395-401.
14. ULLOA N, BUSTOS P, CASTRO G, FRUCHART J, VERA M, FRUCHART J-C, CALVO C. Characterization of monoclonal antibodies against apolipoproteins A-I and A-II. Epitope expression in LpA-I and LpA-I:A-II particles. Hybridoma 1999; 18: 513-20.
15. JUDKINS MP. Selective coronary arteriography, part 1 (A percutaneous transfemoral technique). Radiology 1967; 89: 815-24.
16. FRIEDEWALD WT, LEVY RI, FREDEKICKSON DS. Estimation of the concentration of low density lipoprotein in plasma, without use of preparative centrifuge. Clin Chem 1972; 18: 499-502.
17. SANTOS JL, PÉREZ-BRAVO F, CARRASCO E, ALBALA C. ORINTA: a small software program to learn risk ratio and odds ratio in a elementary course of epidemiology. Medical Education Online 1996; 1-6.
18. DAWBER TR. The Framingham Study: The epidemiology of atherosclerotic disease. Cambridge, Mass, Harvard University Press. 1980.
19. WALLACE RB, ANDERSON RA. Blood lipids, lipid-related measures and the risk of atherosclerotic cardiovascular disease. Epidemiol Rev 1987; 9: 95-119.
20. CASTELLI WP, GARRISON RJ, WILSON PWF, ABBOTT RD, KULOUSDIAN S, KUNEL WD. Incidence of coronary heart disease and lipoproteins levels: The Framingham Study. JAMA 1986; 256: 2835-8.
21. WILSON PWF, ABBOTT RD, CASTELLI WP. High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis 1988; 8: 737-41.
22. FRUCHART JC. Polyclonal, oligoclonal and monoclonal antibody mapping of lipoprotein particles, In Fidge, NH, Nested IP (eds). Atherosclerosis VII. Amsterdam/New York/Oxford, Elsevier SC Pub BV 1986; 287-90.
23. LUC G, FIEVET C, ARVEILER D, EVANS AE, BARD JM, CAMBIEN F, FRUCHART JC, DUCIMETIERE P. Apolipoprotein C-III and apoE in apoB and non-apoB-containing lipoparticles in two populations at contrasting risk for myocardial infarction. The ECTIM Study. J Lipid Res 1996; 37: 508-17.
24. PUCHOIS P, KANDOUSSI A, FIEVET P, FOURRIER JL, BERTRAND M, KOREN E, FRUCHART JC. Apolipoprotein A-I containing lipoproteins in coronary artery disease. Atherosclerosis 1987; 68: 35-40.
25. COSTE-BUREL M, MAINARD F, CHIVOT L, AUGET JL, MADEC Y. Study of lipoprotein particles LpAI and LpAI:AII in patients before coronary bypass surgery. Clin Chem 1990; 36: 1889-91.
26. FRUCHARD JC, AILHAUD G. Apolipoprotein A-containing lipoprotein particles: physiological role, quantification, and clinical significance. Clin Chem 1992; 38: 793-7.
27. BARBARAS R, PUCHOIS P, FRUCHART JC, AIHLAUD G. Cholesterol efflux from cultured adipose cells is mediated by LpA-I particles but not LpA-I:A-II particles. Biochem Biophys Res Commun 1987; 142: 63-9.
28. BARKIA A, PUCHOIS P, GHALIM N ET AL. Differential role of apolipoproteins AI containing particle in cholesterol efflux from adipose cells. Atherosclerosis 1991; 87: 135-46.
29. RUBIN EM. Studies of lipoprotein (a) and high density lipoprotein in transgenic mice. Atherosclerosis 1994; 110: (Suppl.) S77-S81.